文献速递妇科

2型糖尿病患者中降糖药物、他汀类药物与子宫内膜样癌风险

Antidiabetic medication, statins and the risk of endometrioid endometrial cancer in patients with type 2 diabetes.
PubMed 文献 · Gynecol Oncol · 2017-06-20

基于FinDM糖尿病登记库的92,366例新诊断2型糖尿病女性回顾性队列,随访期间观察到590例子宫内膜样癌。巢式病例对照分析显示,二甲双胍(HR 1.24,95%CI 1.02-1.51)和其他口服降糖药(HR 1.25,95%CI 1.04-1.50)与子宫内膜样癌发病增加相关,他汀类药物呈负相关(HR 0.78,95%CI 0.65-0.94);全队列分析支持该发现。

要点

  • 二甲双胍使用与子宫内膜样癌发病增加相关(HR 1.24,95%CI 1.02-1.51),未显示降低风险。
  • 其他口服降糖药同样与发病增加相关(HR 1.25,95%CI 1.04-1.50),与二甲双胍之间无差异。
  • 他汀类药物使用与子宫内膜样癌发病呈负相关(HR 0.78,95%CI 0.65-0.94)。

核心结论

  • 在2型糖尿病女性中,使用二甲双胍或其他口服降糖药与子宫内膜样癌风险降低无关。
  • 他汀类药物在该人群中与子宫内膜样癌呈负相关。

研究设计与样本

  • 回顾性队列研究,数据来自FinDM糖尿病登记库,纳入92,366例新诊断2型糖尿病女性。
  • 随访期间观察到590例子宫内膜样癌。
  • 采用泊松回归估计风险比(HR)及95%置信区间(95%CI)。
  • 进行巢式病例对照分析,每个子宫内膜样癌病例按年龄和糖尿病病程匹配最多20例对照。
  • 采用条件logistic回归估计从未/曾经使用及累积使用不同降糖药和他汀的HR。

主要发现

  • 巢式病例对照分析中,与未使用降糖药相比,二甲双胍使用与子宫内膜样癌发病增加相关(HR 1.24,95%CI 1.02-1.51)。
  • 其他口服降糖药使用与子宫内膜样癌发病增加相关(HR 1.25,95%CI 1.04-1.50)。
  • 二甲双胍使用者与其他口服降糖药使用者之间未观察到差异。
  • 他汀类药物使用与子宫内膜样癌发病呈负相关(HR 0.78,95%CI 0.65-0.94)。
  • 全队列分析结果支持上述发现。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To gain further evidence of an association between the incidence of endometrial cancer (EC) and the use of metformin, other antidiabetic medication (ADM) and statins in women with type 2 diabetes (T2D). METHODS: A retrospective cohort of 92,366 women with newly diagnosed T2D was obtained from a diabetes register (FinDM). 590 endometrioid ECs were observed during the follow-up time. Poisson regression was utilized to estimate the hazard ratios (HRs) with 95% confidence intervals (95% CIs) of the endometrioid EC in relation to the use of metformin, other oral ADM, insulin and statins. Nested case-control analyses were performed, where up to 20 controls were matched for age and duration of DM for each EC case. The HRs were estimated by conditional logistic regression for never/ever and cumulative use of different forms of ADM and statins. RESULTS: In the case-control analyses the use of metformin (HR 1.24, 95% CI 1.02-1.51) and other oral ADM (HR 1.25, 95% CI 1.04-1.50) was associated with an increased incidence of endometrioid EC compared to no ADM use. No difference was observed between metformin users and those using other oral ADMs. The use of statins was inversely related to the incidence of endometrioid EC (HR 0.78, 95% CI 0.65-0.94). Results from the full cohort analysis supported this finding. CONCLUSIONS: In our study the use of metformin or other oral forms of ADM was not associated with a lowered risk of endometrioid EC in women with T2D. Instead statins were observed to be inversely associated with endometrioid EC in this population.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Arima R, Marttila M, Hautakoski A, et al. Antidiabetic medication, statins and the risk of endometrioid endometrial cancer in patients with type 2 diabetes. Gynecol Oncol. 2017. PMID: 28645427. doi:10.1016/j.ygyno.2017.06.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。